Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkin's lymphoma patients
Autor: | Renata Huzjan Korunic, Petar Gaćina, Vlatko Pejša, Željko Prka, Zdravko Mitrović, Željko Jonjić, Marija Ivic, Ozren Jakšić, Josipa Vlasac Glasnovic, Amina Fazlić Džankić, Marko Lucijanic, Mario Piršić |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty Constitutional symptoms medicine.medical_treatment 030204 cardiovascular system & hematology Gastroenterology Extranodal Disease 03 medical and health sciences Hodgkin Disease* / diagnostic imaging 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine Stage (cooking) Proportional Hazards Models Psoas Muscles Retrospective Studies Chemotherapy business.industry Hazard ratio Hodgkin Disease* / drug therapy General Medicine medicine.disease Prognosis Hodgkin Disease Lymphoma Sarcopenia Lymphoproliferative neoplasm Prognostication Progression Survival business Body mass index Psoas Muscles* / diagnostic imaging |
Zdroj: | Wiener klinische Wochenschrift. 134(1-2) |
ISSN: | 1613-7671 |
Popis: | We retrospectively investigated clinical and prognostic significance of psoas muscle index (PMI) calculated as total psoas muscle area at L3 vertebra level obtained from baseline computed tomography (CT) scans in 49 newly diagnosed classical Hodgkin's lymphoma (cHL) patients prior to specific treatment. Median PMI was 572.5 mm2/m2 and was significantly higher in males (P < 0.001), patients with higher body mass index (BMI, P < 0.001), absence of extranodal disease (P = 0.037), higher absolute lymphocyte count (P = 0.037), higher hemoglobin (P = 0.010) and lower lactate dehydrogenase (LDH, P = 0.050). There were no significant associations with age, disease subtype, presence of constitutional symptoms, Ann Arbor disease stage, presence of advanced disease or international prognostic score. Patients with lower PMI had significantly worse PFS (hazard ratio [HR] 4.91 ; P = 0.009). This phenomenon persisted in the multivariate model (HR = 5.09 ; P = 0.042) adjusted for International Prognostic Score (IPS) and chemotherapy type. |
Databáze: | OpenAIRE |
Externí odkaz: |